SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SAN DIEGO, Jan. 25, 2017 -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on January 26, 2017, under the symbol "ANAB." In addition, AnaptysBio has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. The offering is expected to close on January 31, 2017, subject to customary closing conditions.
Credit Suisse and Stifel are acting as joint book-running managers for the offering. JMP Securities and Wedbush PacGrow are acting as co-managers.
A registration statement relating to these securities was filed with the Securities and Exchange Commission and declared effective on January 25, 2017. The offering is being made only by means of a prospectus. Copies of the final prospectus for the offering may be obtained, when available, from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact: Monique Allaire THRUST Investor Relations 781.631.0759 [email protected]
